Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 1
1981 3
1982 4
1983 6
1988 2
1989 2
1991 1
1996 1
2000 1
2001 1
2003 1
2004 1
2005 1
2006 3
2007 1
2008 1
2009 1
2010 1
2012 1
2017 2
2018 5
2019 4
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

48 results
Results by year
Filters applied: . Clear all
Page 1
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.
Adusumilli PS, Zauderer MG, Rivière I, Solomon SB, Rusch VW, O'Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, Pineda J, Perez-Johnston R, Tan KS, Daly B, Araujo Filho JA, Ngai D, McGee E, Vincent A, Diamonte C, Sauter JL, Modi S, Sikder D, Senechal B, Wang X, Travis WD, Gönen M, Rudin CM, Brentjens RJ, Jones DR, Sadelain M. Adusumilli PS, et al. Among authors: senechal b. Cancer Discov. 2021 Nov;11(11):2748-2763. doi: 10.1158/2159-8290.CD-21-0407. Epub 2021 Jul 15. Cancer Discov. 2021. PMID: 34266984 Free PMC article. Clinical Trial.
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M. Park JH, et al. Among authors: senechal b. N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919. N Engl J Med. 2018. PMID: 29385376 Free PMC article. Clinical Trial.
Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy.
Wudhikarn K, Flynn JR, Rivière I, Gönen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, Halton EF, Diamonte C, Davila ML, Sadelain M, Brentjens RJ, Park JH. Wudhikarn K, et al. Among authors: senechal b. Blood. 2021 Aug 19;138(7):531-543. doi: 10.1182/blood.2020009515. Blood. 2021. PMID: 33851211 Free PMC article. Clinical Trial.
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.
Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, Kobos R, Forlenza CJ, Steinherz P, Prockop S, Boulad F, Spitzer B, Cancio MI, Boelens JJ, Kung AL, Khakoo Y, Szenes V, Park JH, Sauter CS, Heller G, Wang X, Senechal B, O'Reilly RJ, Riviere I, Sadelain M, Brentjens RJ. Curran KJ, et al. Among authors: senechal b. Blood. 2019 Dec 26;134(26):2361-2368. doi: 10.1182/blood.2019001641. Blood. 2019. PMID: 31650176 Free PMC article. Clinical Trial.
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Sauter CS, Senechal B, Rivière I, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Singh AN, Szenes VZ, Yoo S, Dogan A, Wang Y, Moskowitz CH, Giralt S, Matasar MJ, Perales MA, Curran KJ, Park J, Sadelain M, Brentjens RJ. Sauter CS, et al. Among authors: senechal b. Blood. 2019 Aug 15;134(7):626-635. doi: 10.1182/blood.2018883421. Epub 2019 Jul 1. Blood. 2019. PMID: 31262783 Free PMC article. Clinical Trial.
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ. Santomasso BD, et al. Among authors: senechal b. Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7. Cancer Discov. 2018. PMID: 29880584 Free PMC article. Clinical Trial.
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.
Perica K, Flynn J, Curran KJ, Rivere I, Wang X, Senechal B, Halton E, Diamonte C, Pineda J, Bernal Y, Gonen M, Sadelain M, Brentjens RJ, Park JH. Perica K, et al. Among authors: senechal b. Leukemia. 2021 Nov;35(11):3268-3271. doi: 10.1038/s41375-021-01196-3. Epub 2021 Mar 8. Leukemia. 2021. PMID: 33686196 Free PMC article. No abstract available.
Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing.
Wang X, Borquez-Ojeda O, Stefanski J, Du F, Qu J, Chaudhari J, Thummar K, Zhu M, Shen LB, Hall M, Gautam P, Wang Y, Sénéchal B, Sikder D, Adusumilli PS, Brentjens RJ, Curran K, Geyer MB, Mailankhody S, O'Cearbhaill R, Park JH, Sauter C, Slovin S, Smith EL, Rivière I. Wang X, et al. Among authors: senechal b. Mol Ther Methods Clin Dev. 2021 Jul 16;22:377-387. doi: 10.1016/j.omtm.2021.06.014. eCollection 2021 Sep 10. Mol Ther Methods Clin Dev. 2021. PMID: 34514029 Free PMC article.
[Otoplasties].
Senechal G, Senechal B. Senechal G, et al. Among authors: senechal b. J Fr Otorhinolaryngol Audiophonol Chir Maxillofac. 1983 Jun;32(6):378-83. J Fr Otorhinolaryngol Audiophonol Chir Maxillofac. 1983. PMID: 6224913 French. No abstract available.
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Palomba ML, Halton E, Bernal Y, van Leeuwen DG, Sadelain M, Park JH, Brentjens RJ. Geyer MB, et al. Among authors: senechal b. JCI Insight. 2019 Apr 2;5(9):e122627. doi: 10.1172/jci.insight.122627. JCI Insight. 2019. PMID: 30938714 Free PMC article. Clinical Trial.
48 results